The IL-23/IL-17 axis has been implicated in driving intrinsic inflammatory activity and triggering the clinical onset of rheumatoid arthritis, primarily in animal models, suggesting that early intervention in the pre–rheumatoid arthritis phase could potentially lead to clinical improvement (111, 119). This evidence concerns the gene IL23A and rheumatoid arthritis.